AbbVie is a research-based biopharmaceutical company focused on developing and marketing innovative therapies in several key therapeutic areas including immunology, oncology, neuroscience, and ophthalmology.
An overview of a recently matured corporate bond issued by AbbVie, a leading global biopharmaceutical company, reveals the following key details. Identified by ISIN US00287YBN85 and CUSIP 00287YBN8, this bond was issued in the United States with a total original size of $750,000,000. It featured an annual coupon rate of 0.897%, with interest payments disbursed quarterly, and a minimum purchase size set at $2,000. The issuer, AbbVie Inc., headquartered in North Chicago, Illinois, was established in 2013 as a spin-off from Abbott Laboratories, and is dedicated to discovering and delivering innovative medicines across key therapeutic areas such as immunology, oncology, neuroscience, eye care, and virology, reflecting a global commitment to addressing serious health challenges. Reflecting its financial health and stability, the bond was rated BBB+ by Standard & Poor's and Baa2 by Moody's, both indicative of investment-grade credit quality. This specific security reached its maturity on November 20, 2022, and has since been fully redeemed at its par value of 100% in USD.
|
Français
Italiano
United States
US00287YBN85 ( in USD )
